End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
770,000 KRW | -1.28% | -1.41% | +1.32% |
04-25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
04-25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
ETFs positioned on Samsung Biologics Co.,Ltd.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 2 M€ | -14.14% | ||
0.92% | 11 M€ | -.--% | - | |
0.43% | 15 M€ | +11.24% | ||
0.15% | 441 M€ | +4.60% | - | |
0.15% | 2,808 M€ | +5.90% | - | |
0.15% | 149 M€ | +2.17% | - | |
0.13% | 4 M€ | -4.41% | - | |
0.07% | 11 M€ | +1.79% | ||
0.05% | 117 M€ | +1.11% | - | |
0.04% | 7 M€ | +1.95% | - | |
0.02% | 34 M€ | +6.71% | - | |
0.01% | 302 M€ | +3.80% | - | |
0.01% | 39 M€ | +3.67% | - | |
0.01% | 389 M€ | +6.83% | - | |
0.01% | 108 M€ | +2.03% | - | |
0.01% | 17 M€ | +1.44% | - | |
0.01% | 147 M€ | +4.88% | - | |
0.01% | 52 M€ | -0.60% | - | |
0.01% | 8 M€ | -0.60% | - | |
0.00% | 7 M€ | +0.11% | - | |
0.00% | 34 M€ | +2.14% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.32% | 39.82B | |
-4.66% | 86.13B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- A207940 Stock
- Funds and ETFs Samsung Biologics Co.,Ltd.